Centanafadine

Centanafadine
Systematic (IUPAC) name
	(1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
Clinical data
Legal status	Investigational New Drug;
Identifiers
CAS Number	924012-43-1
PubChem	CID 16095349
ChemSpider	17253639
Chemical data
Formula	C15H15N
Molar mass	209.28 g/mol
	SMILES C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4 ;
	InChI InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1 ; Key:HKHCSWPSUSWGLI-CABCVRRESA-N ;

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) under development by Neurovance in collaboration with Euthymics Bioscience as a treatment for attention deficit hyperactivity disorder (ADHD) that inhibits the reuptake of norepinephrine, dopamine and serotonin with a ratio of 1:6:14, respectively.^[1]^[2]^[3] As of August 2015, it is in phase II clinical trials.[1]

References[edit]

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.